Tags

Type your tag names separated by a space and hit enter

Treatment of latent tuberculosis infection.
Ther Adv Respir Dis. 2013 Dec; 7(6):351-6.TA

Abstract

Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries. Clinical trials of treatment of latent TB conducted over several decades have demonstrated that preventive treatment can reduce the risk of developing active TB up to 90%. Although 9 months of daily, self-administered isoniazid has been the most widely used and recommended regimen for the treatment of latent infection, other regimens such as 3 months of daily isoniazid and rifampin, or 4 months of daily rifampin alone have also been recommended and used. Most recently, a 12-dose regimen of once-weekly isoniazid and rifapentine has been shown to be noninferior to 9 months of daily isoniazid in a large and well conducted clinical trial. Adoption of such a regimen on a large scale could have significant implications for TB elimination efforts.

Authors+Show Affiliations

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24056289

Citation

Parekh, Madhavi J., and Neil W. Schluger. "Treatment of Latent Tuberculosis Infection." Therapeutic Advances in Respiratory Disease, vol. 7, no. 6, 2013, pp. 351-6.
Parekh MJ, Schluger NW. Treatment of latent tuberculosis infection. Ther Adv Respir Dis. 2013;7(6):351-6.
Parekh, M. J., & Schluger, N. W. (2013). Treatment of latent tuberculosis infection. Therapeutic Advances in Respiratory Disease, 7(6), 351-6. https://doi.org/10.1177/1753465813503028
Parekh MJ, Schluger NW. Treatment of Latent Tuberculosis Infection. Ther Adv Respir Dis. 2013;7(6):351-6. PubMed PMID: 24056289.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of latent tuberculosis infection. AU - Parekh,Madhavi J, AU - Schluger,Neil W, Y1 - 2013/09/20/ PY - 2013/9/24/entrez PY - 2013/9/24/pubmed PY - 2014/6/17/medline KW - Tuberculosis KW - infection KW - isoniazid KW - latent KW - rifampin KW - rifapentine SP - 351 EP - 6 JF - Therapeutic advances in respiratory disease JO - Ther Adv Respir Dis VL - 7 IS - 6 N2 - Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries. Clinical trials of treatment of latent TB conducted over several decades have demonstrated that preventive treatment can reduce the risk of developing active TB up to 90%. Although 9 months of daily, self-administered isoniazid has been the most widely used and recommended regimen for the treatment of latent infection, other regimens such as 3 months of daily isoniazid and rifampin, or 4 months of daily rifampin alone have also been recommended and used. Most recently, a 12-dose regimen of once-weekly isoniazid and rifapentine has been shown to be noninferior to 9 months of daily isoniazid in a large and well conducted clinical trial. Adoption of such a regimen on a large scale could have significant implications for TB elimination efforts. SN - 1753-4666 UR - https://www.unboundmedicine.com/medline/citation/24056289/Treatment_of_latent_tuberculosis_infection_ L2 - https://journals.sagepub.com/doi/10.1177/1753465813503028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -